Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 10
1999 9
2000 22
2001 31
2002 33
2003 25
2004 66
2005 83
2006 96
2007 127
2008 181
2009 268
2010 408
2011 480
2012 633
2013 711
2014 792
2015 842
2016 912
2017 924
2018 762
2019 662
2020 634
2021 623
2022 532
2023 484
2024 143

Text availability

Article attribute

Article type

Publication date

Search Results

9,167 results

Results by year

Filters applied: . Clear all
Page 1
Everolimus.
Hasskarl J. Hasskarl J. Recent Results Cancer Res. 2018;211:101-123. doi: 10.1007/978-3-319-91442-8_8. Recent Results Cancer Res. 2018. PMID: 30069763 Review.
Everolimus shows promising clinical activity in additional indications. ...For a review on everolimus as immunosuppressant, please consult other sources....
Everolimus shows promising clinical activity in additional indications. ...For a review on everolimus as immunosuppressant, pl …
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.
Lee L, Ito T, Jensen RT. Lee L, et al. Expert Opin Pharmacother. 2018 Jun;19(8):909-928. doi: 10.1080/14656566.2018.1476492. Epub 2018 May 24. Expert Opin Pharmacother. 2018. PMID: 29757017 Free PMC article.
Since the initial approval of everolimus in 2011, there have been a number of important changes in therapeutic/diagnostic modalities as well as classification/staging systems of neuroendocrine tumors (NETs), which can significantly impact the use of everolimus in pa …
Since the initial approval of everolimus in 2011, there have been a number of important changes in therapeutic/diagnostic modalities …
Everolimus: Longer-Term CERTITUDE.
Mousa OY, Keaveny AP. Mousa OY, et al. Liver Transpl. 2019 Dec;25(12):1745-1746. doi: 10.1002/lt.25659. Liver Transpl. 2019. PMID: 31606937 No abstract available.
Everolimus-Eluting Stent-induced Pneumonitis.
Kobayashi H. Kobayashi H. Am J Respir Crit Care Med. 2022 Mar 15;205(6):12-13. doi: 10.1164/rccm.202103-0565IM. Am J Respir Crit Care Med. 2022. PMID: 34491881 No abstract available.
Effects of Everolimus in Modulating the Host Immune Responses against Mycobacterium tuberculosis Infection.
Raien A, Davis S, Zhang M, Zitser D, Lin M, Pitcher G, Bhalodia K, Subbian S, Venketaraman V. Raien A, et al. Cells. 2023 Nov 18;12(22):2653. doi: 10.3390/cells12222653. Cells. 2023. PMID: 37998388 Free PMC article. Review.
Investigating further clinical trials and their use of pathway inhibitors is necessary in order to ascertain their potential for TB treatment. This paper is particularly focused on the drug everolimus, an mTOR inhibitor. One of the first clinical trials sponsored by the Au …
Investigating further clinical trials and their use of pathway inhibitors is necessary in order to ascertain their potential for TB treatmen …
Durable polymer everolimus-eluting stents: history, current status and future prospects.
Rodríguez-Arias JJ, Ortega-Paz L, Brugaletta S. Rodríguez-Arias JJ, et al. Expert Rev Med Devices. 2020 Jul;17(7):671-682. doi: 10.1080/17434440.2020.1784005. Epub 2020 Jun 30. Expert Rev Med Devices. 2020. PMID: 32543934 Review.
INTRODUCTION: Coronary percutaneous interventions have evolved from plain old balloon angioplasty (POBA) to stent implantation, which itself evolved from bare-metal stents (BMS) to the new biodegradable stents which try to restore endothelial function. Currently, the most commonl …
INTRODUCTION: Coronary percutaneous interventions have evolved from plain old balloon angioplasty (POBA) to stent implantation, which itself …
Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives.
Falkowski S, Woillard JB. Falkowski S, et al. Ther Drug Monit. 2019 Oct;41(5):568-574. doi: 10.1097/FTD.0000000000000628. Ther Drug Monit. 2019. PMID: 30913132 Review.
The last consensus conference about the TDM of everolimus states that for the use of everolimus in oncology, "further studies are required to determine the clinical utility of TDM for everolimus in oncology settings." In this review, the authors will discuss …
The last consensus conference about the TDM of everolimus states that for the use of everolimus in oncology, "further studies …
Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?
Witzke O, Sommerer C, Arns W. Witzke O, et al. Transplant Rev (Orlando). 2016 Jan;30(1):3-12. doi: 10.1016/j.trre.2015.09.001. Epub 2015 Sep 18. Transplant Rev (Orlando). 2016. PMID: 26603484 Review.
Two main everolimus-based strategies have been pursued to facilitate calcineurin inhibitor (CNI) reduction after kidney transplantation: (i) everolimus with reduced CNI exposure from time of transplant and (ii) pre-emptive introduction of everolimus with CNI …
Two main everolimus-based strategies have been pursued to facilitate calcineurin inhibitor (CNI) reduction after kidney transplantati …
Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters.
De Simone P, Bronzoni J, Martinelli C. De Simone P, et al. Rev Esp Enferm Dig. 2022 Jun;114(6):312-313. doi: 10.17235/reed.2022.8902/2022. Rev Esp Enferm Dig. 2022. PMID: 35545915 Free article.
The current edition of the journal features a Spanish, nationwide, multi-institutional study by Gomez Bravo MA et al. exploring the advantages of everolimus (EVR)-facilitated tacrolimus (TAC) minimization versus TAC in combination with mycophenolate mofetil (MMF) after liv …
The current edition of the journal features a Spanish, nationwide, multi-institutional study by Gomez Bravo MA et al. exploring the advantag …
Everolimus in de novo liver transplant recipients: a systematic review.
Tang CY, Shen A, Wei XF, Li QD, Liu R, Deng HJ, Wu YZ, Wu ZJ. Tang CY, et al. Hepatobiliary Pancreat Dis Int. 2015 Oct;14(5):461-9. doi: 10.1016/s1499-3872(15)60419-2. Hepatobiliary Pancreat Dis Int. 2015. PMID: 26459721 Review.
BACKGROUND: Everolimus has no nephrotoxicity and is used to treat patients with post-liver transplant chronic renal insufficiency. ...Everolimus combined with low-dose CNI decreases the risk of tBPAR one year after liver transplant, but everolimus administere …
BACKGROUND: Everolimus has no nephrotoxicity and is used to treat patients with post-liver transplant chronic renal insufficiency. .. …
9,167 results

Searches related to "everolimus"